Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector news 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

07/01/2013 | 07:27am US/Eastern
   By Melodie Warner 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
React to this article
03:37p TEVA PHARMACEUTICAL : BRIEF: Teva's launches generic prostate treatment in US
10/12 TEVA PHARMACEUTICAL : Announces Exclusive Launch of Generic Avodart® Capsules in..
10/08 TEVA PHARMACEUTICAL : Reinforces Leadership Position in Respiratory with Acquisi..
10/08 TEVA PHARMACEUTICAL : Healthbox Portfolio Company Gecko Health Innovations is Ac..
10/08 TEVA PHARMACEUTICAL : BRIEF: 40mg Copaxone approved in Russia
10/08 TEVA PHARMACEUTICAL : Important New Data from Teva's TEV-48125 Phase 2B Migraine..
10/08 TEVA PHARMACEUTICAL : Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/m..
10/07 ACTIVE BIOTECH : partner Teva presents data on laquinimod for the treatment of m..
10/07 ACTIVE BIOTECH : partner Teva presents data on laquinimod for the treatment of m..
10/06DJCorrection to Alkermes Story From Oct. 5
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Income Statement Evolution
More Financials